跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 146 条关于
“NOTUS”
全部
146
临床试验
85
药物
7
机构
9
资讯
45
去年
Dupilumab Shows Promise in Phase 3 NOTUS Trial for Moderate-to-Severe COPD
2年前
Dupixent Shows Clinically Meaningful Benefit in COPD Patients with Type 2 Inflammation
2年前
Dupixent Approved by FDA as First Biologic for COPD with Eosinophilic Phenotype
去年
Dupixent Approved in China as First Biologic for COPD Patients
2年前
MHRA Approves Sanofi/Regeneron's Dupixent for Uncontrolled COPD
去年
Dupixent Gains Momentum: EU Approvals for Eosinophilic Esophagitis and COPD, US Approval for COPD
2年前
FDA Nears Decisions on Vanda, Zevra, Heron, Merck, BMS, Sanofi/Regeneron
2年前
FDA Nears Decisions on Key Therapies for Gastroparesis, Niemann-Pick Disease, Schizophrenia, COPD, Mesothelioma, and Post-Surgical Pain
11个月前
Dupilumab Reduces Severe COPD Exacerbations Regardless of Cardiovascular and Metabolic Comorbidities
去年
Dupilumab Shows Sustained Lung Function Improvements in COPD Patients with Type 2 Inflammation
第 1 页,共 5 页
上一页
下一页